Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide
- Kathleen Dungan, MD and
- John B. Buse, MD, PhD
Abstract
IN BRIEF
Therapies based on the incretin hormone glucagon-like peptide 1 are novel treatment options for type 2 diabetes that act through a variety of complementary mechanisms. Exenatide, which will likely become the first application to reach the market, has shown promise in phase III trials in reducing hemoglobin A1c without causing significant hypoglycemia or weight gain.
Footnotes
-
Kathleen Dungan, MD, is a subspecialty fellow in the Division of Endocrinology, Department of Medicine at the University of North Carolina School of Medicine in Chapel Hill. John B. Buse, MD, PhD, is an associate professor in the Division of Endocrinology and Division of General Medicine and Clinical Epidemiology, Department of Medicine at the same institution. He is the director of the Diabetes Care Center at the University of North Carolina. He is also an associate editor of Clinical Diabetes.
-
Note of disclosure: The University of North Carolina has received support related to Dr. Buse's research and consulting activities from Amylin, Eli Lilly, and Novartis, companies actively involved in developing pharmaceuticals that modify the acivity of the GLP-1 system.
- American Diabetes Association
